Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urinary Tumor DNA-Guided Systemic Immunotherapy in VHR NMIBC
NCT07475403Phase 2Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Mar 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Non-muscle-invasive bladder cancer (NMIBC), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Event-Free Survival at 2 years. Started Mar 2026; status: recruiting.
02
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07475403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07475403.